A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

This was a 3-part study designed to explore the safety and tolerability of escalating doses
of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm
RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy
of PLX3397 600 mg twice daily (BID) administered in combination with weekly paclitaxel in
participants with advanced, metastatic or non-resectable, platinum-resistant or -refractory
epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.